Nimodipine is a widely used medication for treating delayed cerebral ischemia (DCI) after subarachnoid hemorrhage. When\nadministrated orally or intravenously, systemic hypotension is an undesirable side effect. Intracranial subarachnoid delivery of\nnimodipine during aneurysm clipping may bemore efficient way of preventing vasospasm and DCI due to higher concentration of\nnimodipine in cerebrospinal fluid (CSF).Therisk of systemic hypotension may also be decreasedwith intracranial delivery.We used\nanimal models to evaluate the feasibility of surgically implanting a silica-based nimodipine releasing implant into the subarachnoid\nspace through a frontotemporal craniotomy. Concentrations of released nimodipine were measured fromplasma samples and CSF\nsamples. Implant degradation was followed using CT imaging. After completing the recovery period, full histological examination\nwas performed on the brain and meninges. The in vitro characteristics of the implant were determined. Our results show that the\nbiodegradable silica-based implant can be used for an intracranial drug delivery systemand nomajor histopathological foreign body\nreactions were observed. CT imaging is a feasible method for determining the degradation of silica implants in vivo.The sustained\nrelease profiles of nimodipine in CSF were achieved. Compared to a traditional treatment, higher nimodipine CSF/plasma ratios\ncan be obtained with the implant.
Loading....